Korro Bio, Inc. Common Stock (KRRO)
PHARMACEUTICAL PREPARATIONS
Korro Bio, Inc. Common Stock (KRRO) is listed on Nasdaq, where it has traded since November 6, 2023.
- Listed On
- Nasdaq
- Listed Since
- November 6, 2023
- Employees
- 57
- Market Cap
- $141M
About Korro Bio, Inc. Common Stock
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 103 institutions reported holding KRRO, with 14.4 million shares worth $190.1 million in aggregate. The largest reported holder was Lynx1 Capital Management, with 1.5 million shares worth $20.3 million. Of the 5 largest holders listed below, 2 reduced their positions and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Lynx1 Capital Management | 1,538,296 | $20M | Unchanged |
| Nea Management Company | 1,297,893 | $17M | Unchanged |
| VR Adviser | 1,009,500 | $13M | Unchanged |
| Atlas Venture Life Science Advisors | 962,884 | $13M | Reduced 15.32% |
| Balyasny Asset Management | 951,783 | $13M | Reduced 8.49% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is KRRO?
Korro Bio, Inc. Common Stock (KRRO) is listed on Nasdaq, where it has traded since November 6, 2023.
Who are the largest institutional holders of KRRO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of KRRO were Lynx1 Capital Management, Nea Management Company and VR Adviser.
How many institutions own KRRO?
103 institutions reported a position in KRRO for the quarter ended June 30, 2026, worth $190.1 million in total.
Did institutions buy or sell KRRO last quarter?
Of the 5 largest reported holders, 2 reduced their positions and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for KRRO.
Every reported institutional holder, plus insider and congressional trades in KRRO, on SentiSense.